Author

T. Subramanian

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Bhargava· 1 shared A. D. Maturana· 1 shared A. K. Zinzuvadia· 1 shared B. Cagir· 1 shared J. D. Greenlee· 1 shared K. Liu· 1 shared M. Lopez-Cavestany· 1 shared M. R. King· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bhargava

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Divergent outcomes of SAK3, a T-type calcium channel enhancer, in two luminal-A type breast cancer cell lines: T-47D and MCF7

Y. S. Dinesh, T. Subramanian, A. K. Zinzuvadia, A. D. Maturana, A. Bhargava

The paper shows that SAK3, a T-type calcium channel enhancer, causes different effects on proliferation and calcium levels in two luminal-A breast cancer cell lines.

bioRxiv · Nov 16, 2023 · PreprintCancer Biology

Oxaliplatin Resistance in Colorectal Cancer Enhances TRAIL Sensitivity Via Death Receptor 4 Upregulation and Lipid Raft Localization

J. D. Greenlee, M. Lopez-Cavestany, N. Ortiz-Otero, K. Liu, T. Subramanian, B. Cagir, M. R. King

This study shows oxaliplatin-resistant colorectal cancer cells become more sensitive to TRAIL due to increased DR4 expression, palmitoylation, and lipid raft localization.

bioRxiv · Mar 5, 2021Cancer Biology